Drug Development

Oblenio Bio's LBL-051 enters human trials, offering hope for a true "immune reset" and drug-free remission for severe autoimmune disease patients.

Vantage Biosciences has completed enrollment for its oral drug, oruvestat, a potential game-changer for early diabetic retinopathy. This could replace invasive injections.

IDEAYA Biosciences advances its breakthrough melanoma drug toward FDA review while its $1.24B cash runway fuels a deep pipeline targeting cancer's toughest codes.

MGI Tech's strategic alliance with NCSTAR in Queensland is set to accelerate medical breakthroughs by providing a full suite of cutting-edge 'multi-omics' tools.

LabPMM's new global KMT2A MRD test offers ultra-sensitive monitoring for aggressive leukemias, aiming to improve patient outcomes and streamline trials for menin inhibitors.

Pathos AI leverages its Foundry platform to ink a $2.2B deal with Alphamab for a novel cancer drug, signaling a new era of AI-led pharma strategy.

As ProMIS Neurosciences preps its Q2 update, all eyes are on its lead Alzheimer's drug. Can its "sniper-like" precision deliver efficacy without the side effects plaguing the field?

A positive safety review for Molecure's novel sarcoidosis drug OATD-01 de-risks its development, offering new hope for patients and boosting the company's strategic value.

Exicure is settling a $1M debt with stock, a move to preserve its dwindling cash. Can this gamble save its new focus on blood cancer therapy or just delay the inevitable?

Ceruvia Lifesciences secures $8M for a non-hallucinogenic LSD analog to treat cluster headaches, offering a potential breakthrough for a severe pain disorder.

Biocon's Yesafili, an interchangeable biosimilar to the $5.9B eye drug Eylea, launches in the US, promising major cost savings and market disruption.

Fresh off a $260M IPO, Seaport Therapeutics is advancing a de-risked pipeline for depression and anxiety, leveraging its novel platform to unlock new potential.

With blockbuster sales for its MS drug BRIUMVI, TG Therapeutics is raising revenue targets and aggressively expanding its pipeline into new diseases.

With its AI platform generating novel targets, Compugen advances a key ovarian cancer drug while partners AstraZeneca and Gilead push its discoveries forward.

The FDA has fast-tracked a novel peanut allergy therapy from Aravax, signaling a major shift in the multi-billion dollar race to find a lasting solution.

The first Animal Longevity Summit marks a pivotal moment, as research into pet aging and biotech investment converge to create a new frontier in healthspan.

A new partnership aims to treat PTSD with psilocybin, revealing a broader strategy to navigate regulatory mazes and build the clinical infrastructure for a new era of medicine.

NewcelX secured a small but vital $1.4M financing at a 20% premium. It's a bold vote of confidence, but is it enough to outrun a 'going concern' warning?

With cash dwindling and a pivotal trial result looming after a recent failure, Vistagen brings a seasoned drug developer aboard to navigate the turbulence.

With Phase 3 results for Levosimendan imminent and its cash runway secured, Tenax Therapeutics faces a make-or-break moment in the PH-HFpEF space.